NCT02603003View on ClinicalTrials.gov

"theFuzheng Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs"

PHASE1CompletedINTERVENTIONAL

Enrollment

218

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 1, 2019

Study Completion Date

September 1, 2019

Conditions

Non-small Cell Lung Cancer(NSCLC)

Interventions

DRUG

JinFuKang

po.tid.30ml

DRUG

Cisplatin

According to the individual patient's condition

DRUG

Pemetrexed

According to the individual patient's condition

All Listed Sponsors

lead

Shanghai University of Traditional Chinese Medicine

OTHER

NCT02603003 - "theFuzheng Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs" | Biotech Hunter | Biotech Hunter